The Clinical study posted on this thread to support the bioavailability of MetaCurcumin was designed to assess the bioavailability of the NovaSOL® Curcumin, a proprietary micellar curcumin formulation manufactured by AquaNova AG based in Germany, compared to the bioavailability of native and micronized powder. The full study is posted at:
http://onlinelibrary....201300724/full
In this study participants were administered 500mg curcuminoids, containing 410mg curcumin, 80 mg DMC and 10mg BDMC as native powder, micronized powder and liquid micelles. Curcumin micelles were composed by 7% curcumin powder (equivalent to 6% curcumin) and 93% Tween-80.
1) Does the MetaCurcumin formulation include the NovaSOL® Curcumin manufactured by AquaNova? Is this the same formulation as the one used in the clinical study, if not how the MetaCurcumin formulation differs from the NovaSOL® used in the study?
2) How about the “Supplement Facts” of the MetaCurcumin formulation? Which other additives are included in this product? It would be really helpful for us to compare the different product formulations and strengths currently available in the market and also be aware of possible additives and allergens included. Unfortunately the Supplement Facts of the MetaCurcumin formulation don’t appear to be published online, neither on this thread nor at the manufacturer’s page.
3) How about the side effects of the curcumin micelles that were reported by participants in this study?
According to this study approximately 54% of women experienced mild nausea (7 out of 13 women). It could be because of the micellar curcumin staying in the bloodstream for too long or because of others reasons that worth further investigation. A total 12 adverse reactions were reported. However those side effects were not reported when participants took the other 2 formulations.
4) Besides the bioavailability on healthy subjects, are there any published clinical human studies to support the biological activities and therapeutic efficacy of the curcumin micelles in certain conditions like arthritis, inflammation and cognition?
To date no clinical human studies of curcumin micelles are published so far in order to draw conclusions of their therapeutic efficacy on certain clinical conditions, contrary to other popular formulations like Meriva, BCM-95, Theracurmin and Longvida Curcumin which come with multiple clinical trials and some supportive evidence to back up their efficacy.
5) How much micellar curcumin is absorbed by the body tissues where it can show potential biological effectiveness?
Beyond pharmacokinetics like AUC and blood concentration there are multiple factors than can determine the efficacy of certain compounds. The NovaSOL® study includes the following statement “over 98.8% of the ingested curcumin was either excreted via the bile and feces or may have been distributed by body tissues, where it may potentially exert biological activities”.
Edited by Pantheon, 07 July 2017 - 11:25 PM.
